ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 282,22
-1,51%
Dow Jones
42 732,13
0,80%
DAX
19 906,08
-0,49%
Brent Oil
76,195
-0,41%
Bitcoin
99 119,85
0,83%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Royaume-Uni
  5. LSE

  6. Selvita Sa (0RKT) Cours

Selvita Sa

Selvita Sa (0RKT)

LSE
57,00
0,00
(0,00%)
Fermé 06 Janvier 5:30PM
Retardé de 15 minutes

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Statistiques et détails clés

Dernier
57,00
Prix Achat
0,00
Prix Vente
0,00
Volume échangé
0,00
0,00 Fourchette du Jour 0,00
57,00 Plage de 52 semaines 57,00
Cap du marché
1,318B
Clôture Veille
57,00
Ouverture
-
Dernière Transaction
(O)
Dernière heure de transaction
Volume financier
-
VWAP
-
Volume moyen (3 m)
1
Actions en circulation
23 120 000
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-14,31
Bénéfice par action (BPA)
-3,98
Chiffre d'affairess
67,99M
Bénéfice net
-92,11M

À propos de Selvita Sa

Secteur
Chemicals & Chem Preps, Nec
Industrie
Chemicals & Chem Preps, Nec
Site Web
ryvu.com
Siège social
Krakow, Pol
Fondé
-
Selvita Sa est coté dans le secteur Chemicals & Chem Preps de la London Stock Exchange avec le ticker 0RKT. Le dernier cours de clôture d'Selvita était de PLN57,00. Au cours de la dernière année, les actions de Selvita ont été négociées dans une fourchette de prix de PLN 57,00 à PLN 57,00.

Selvita compte actuellement 23 120 000 actions en circulation. La capitalisation boursière d'Selvita est de PLN1,32 milliard. Selvita a un ratio cours/bénéfice (ratio PE) de -14.31.

0RKT Dernières nouvelles

Plus de nouvelles

Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium PR Newswire KRAKOW, Poland, Oct. 23, 2024...

23 Octobre 2024
PR Newswire (US)

Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium PR Newswire KRAKOW, Poland, Oct. 9, 2024...

09 Octobre 2024
PR Newswire (US)

Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit

Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit PR Newswire KRAKOW, Poland, Sept. 23, 2024 ONCO Prime is a cutting-edge drug discovery...

23 Septembre 2024
PR Newswire (US)

Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress

Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress PR Newswire KRAKOW, Poland, June 14, 2024 RVU120 as a single agent showed...

14 Juin 2024
PR Newswire (US)

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting PR Newswire KRAKOW, Poland, March 6, 2024 Updated preclinical data will be...

06 Mars 2024
UK Regulatory

Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS

Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS PR Newswire KRAKOW...

14 Février 2024
UK Regulatory

Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting

Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting PR Newswire KRAKOW, Poland, Nov. 2, 2023 Updated data from the Phase I trial of RVU120...

02 Novembre 2023
PR Newswire (US)

Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update

Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update PR Newswire KRAKOW, Poland, Sept. 28, 2022 KRAKOW, Poland, Sept. 28, 2022 /PRNewswire/ -- Ryvu...

28 Septembre 2022
PR Newswire (US)

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress PR Newswire KRAKOW, Poland, June 10, 2022 - Clinically...

10 Juin 2022
PR Newswire (US)

Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual Meeting

Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual Meeting PR Newswire KRAKOW, Poland, March 8, 2022 KRAKOW, Poland, March 8, 2022 /PRNewswire/ -- Ryvu Therapeutics...

08 Mars 2022
PR Newswire (US)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10057575700DE
400575757457DE
1200575757157DE
2600575757157DE
5200575757057DE
15600575757057DE
26000575757057DE

0RKT - Frequently Asked Questions (FAQ)

What is the current Selvita share price?
The current share price of Selvita is PLN 57,00
How many Selvita shares are in issue?
Selvita has 23 120 000 shares in issue
What is the market cap of Selvita?
The market capitalisation of Selvita is PLN 1,32B
What is the 1 year trading range for Selvita share price?
Selvita has traded in the range of PLN 57,00 to PLN 57,00 during the past year
What is the PE ratio of Selvita?
The price to earnings ratio of Selvita is -14,31
What is the cash to sales ratio of Selvita?
The cash to sales ratio of Selvita is 19,38
What is the reporting currency for Selvita?
Selvita reports financial results in PLN
What is the latest annual turnover for Selvita?
The latest annual turnover of Selvita is PLN 67,99M
What is the latest annual profit for Selvita?
The latest annual profit of Selvita is PLN -92,11M
What is the registered address of Selvita?
The registered address for Selvita is ST. LEONA HENRYKA STERNBACHA 2, KRAKOW, 30-394
What is the Selvita website address?
The website address for Selvita is ryvu.com
Which industry sector does Selvita operate in?
Selvita operates in the CHEMICALS & CHEM PREPS, NEC sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
TCFTheracryf Plc
0,725p
(38,10%)
7,56M
NMTNeometals Ltd
3,50p
(27,27%)
346,81k
SCHOScholium Group Plc
44,00p
(25,71%)
30,65k
FABFusion Antibodies Plc
10,15p
(24,54%)
3,34M
PYXPyx Resources Limited
3,49p
(22,24%)
8,43k
TM1Technology Minerals Plc
0,125p
(-24,24%)
37,21M
QUIZQuiz Plc
0,70p
(-18,60%)
3,67M
SYMESupply@me Capital Plc
0,003p
(-17,81%)
168,35M
OBDOxford Biodynamics Plc
1,20p
(-14,29%)
827,83k
ZENZenith Energy Ltd.
5,25p
(-13,93%)
5,39M
TRPTower Resources Plc
0,0395p
(5,33%)
539,51M
CPXCap-xx Limited
0,1825p
(1,39%)
494M
NTVONativo Resources Plc
0,0019p
(0,00%)
320,16M
DGIDg Innovate Plc
0,0225p
(-13,46%)
208,21M
ENETEthernity Networks Ltd
0,1125p
(2,27%)
207,56M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

LSE
0RKT
Selvita
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés